Medpace (NASDAQ:MEDP) Announces FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 17.970-18.320 for the period, compared to the consensus EPS estimate of 17.680. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Analyst Ratings Changes

Several equities research analysts have commented on MEDP shares. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Truist Financial upped their price objective on shares of Medpace from $609.00 to $633.00 and gave the company a “hold” rating in a report on Friday. Barclays upped their target price on Medpace from $625.00 to $675.00 and gave the company an “equal weight” rating in a research report on Friday. TD Cowen lifted their price objective on shares of Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a research note on Friday. Finally, Robert W. Baird set a $699.00 target price on Medpace in a research report on Friday. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $642.91.

Medpace Trading Up 2.3%

MEDP traded up $15.24 during trading on Friday, reaching $669.20. 309,423 shares of the company’s stock were exchanged, compared to its average volume of 332,400. Medpace has a one year low of $373.00 and a one year high of $684.52. The stock has a market capitalization of $18.68 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 2.91 and a beta of 1.18. The firm has a fifty day moving average price of $611.66 and a two-hundred day moving average price of $537.67.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The business had revenue of $716.00 million during the quarter, compared to analyst estimates of $714.47 million. During the same period last year, the company earned $3.86 EPS. Medpace’s revenue for the quarter was up 8.5% compared to the same quarter last year. Sell-side analysts expect that Medpace will post 17.61 earnings per share for the current year.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 49,018 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the sale, the chief executive officer owned 433,372 shares of the company’s stock, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 336,140 shares of company stock worth $208,008,328 over the last ninety days. 20.50% of the stock is owned by company insiders.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: New $1 billion buyback: Medpace authorized a $1 billion repurchase program, replacing its previous authorization. The plan signals management’s confidence in cash generation and could support earnings per share by reducing the share count. Medpace Announces $1 Billion Stock Buyback Program
• Positive Sentiment: Raised 2026 outlook: The company forecast adjusted EPS of $17.97–$18.32, above the $17.68 analyst consensus, while revenue guidance of $2.8–$2.9 billion is broadly consistent with expectations. Medpace 2026 Guidance and Buyback
• Positive Sentiment: Q3 earnings beat: Medpace reported earnings of $4.84 per share versus the $4.45 consensus estimate, with revenue of approximately $716 million and year-over-year revenue growth of 8.5%. Margin expansion helped drive the earnings outperformance. Medpace Q3 Earnings Beat
• Positive Sentiment: Demand remains healthy: Net new business awards reached $873 million in the third quarter, and ending backlog increased 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace Long-Term Investor Takeaways
• Neutral Sentiment: Analyst targets moved higher but ratings remain cautious: TD Cowen raised its target to $673 from $492 and kept a “hold” rating, while Deutsche Bank increased its target to $650 and also maintained “hold.” These revisions acknowledge the improved outlook but imply limited upside at recent trading levels. TD Cowen Medpace Rating
• Negative Sentiment: Valuation remains a concern: Commentary following the results questioned whether MEDP is already pricing in much of its growth, with some analysis describing the shares as materially overvalued despite the earnings beat. This may explain the initial post-earnings hesitation.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.